Oral anticoagulant-proton pump inhibitor interactions: A pharmacovigilance assessment using disproportionality and interaction analyses
Main Article Content
Keywords
Warfarin, Dabigatran, Rivaroxaban, Apixaban, Omeprazole, Esomeprazole
Abstract
Objective: Oral anticoagulants operate within a narrow therapeutic window, with upper gastrointestinal bleeding representing a significant safety concern. While proton pump inhibitors (PPIs) have demonstrated gastroprotective properties, existing literature presents conflicting evidence regarding their interactions with oral anticoagulants. Methods: A detailed analysis was conducted using the United States Food and Drug Administration Adverse Event Reporting System (USFDA AERS) database. The study examined interactions between five oral anticoagulants (warfarin, apixaban, dabigatran, edoxaban, and rivaroxaban) and six PPIs (lansoprazole, dexlansoprazole, omeprazole, esomeprazole, pantoprazole, and rabeprazole). A case-non-case disproportionality analysis was employed, utilizing both frequentist and Bayesian data mining algorithms. Interaction Signal Scores were calculated to evaluate interaction strengths. Results: Of 29,163,222 initial reports, 5,222 met inclusion criteria. Significant interactions were identified across multiple anticoagulant-PPI combinations. Notably, dabigatran combined with omeprazole or pantoprazole, and apixaban with most PPIs, demonstrated increased hemorrhagic event risks. Gastrointestinal hemorrhage interactions were most extensive, with significant signals across multiple drug combinations. Certain combinations, like rivaroxaban-esomeprazole, showed protective effects, while others, such as rivaroxaban-rabeprazole, exhibited increased venous thromboembolic event risks. Conclusion: This pharmacovigilance analysis reveals complex interactions between oral anticoagulants and PPIs, highlighting the need for individualized risk assessment. Healthcare providers should carefully monitor patients receiving these combinations, considering potential hemorrhagic complications and patient-specific risk factors.
References
2. Ray WA, Chung CP, Murray KT, et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterology. 2016;151(6):1105–12.e10.
3. Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology. 2015;149(3):586–95.e3.
4. Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. 2018;320(21):2221–30.
5. Ray WA, Chung CP, Murray KT, et al. Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding. Gastroenterology. 2016;151(6):1105-1112.e10.
6. Lee HJ, Kim HK, Kim BS, et al. Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy. PLoS One. 2021;16(6):e0253310.
7. Henriksen DP, Stage TB, Hansen MR, et al. The potential drug-drug interaction between proton pump inhibitors and warfarin. Pharmacoepidemiol Drug Saf. 2015;24(12):1337-40.
8. Hata M, Hayasaka M, Sezai A, et al. Proton pump inhibitors may increase the risk of delayed bleeding complications after open heart surgery if used concomitantly with warfarin. Thorac Cardiovasc Surg. 2008;56(5):274-7.
9. Using warfarin with proton pump inhibitors (PPIs). Available at: https://www.sps.nhs.uk/articles/using-warfarin-with-proton-pump-inhibitors-ppis/#:~:text=Combined%20use%20of%20warfarin%20with,of%20increased%20INR%20and%20bleeding. (Accessed on 27 November 2024).
10. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47:285-95.
11. Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63:321–328.
12. Schnierer M, Samoš M, Bolek T, et al. The Effect of Proton Pump Inhibitor Withdrawal on Dabigatran Etexilate Plasma Levels in Patients With Atrial Fibrillation: A Washout Study. J Cardiovasc Pharmacol. 2020;75(4):333-335.
13. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19(1):25-35.
14. Manikandan P, Nagini S. Cytochrome P450 Structure, Function and Clinical Significance: A Review. Curr Drug Targets. 2018;19(1):38-54.
15. Ko J-W, Sukhova N, Thacker D, et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25:853-862.
16. FDA’s Adverse Event Reporting System. Available at: https://www.fda.gov/drugs/surveillance/fdas-adverse-event-reporting-system-faers (October 27, 2024).
17. Caster O, Aoki Y, Gattepaille LM, et al. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations. Drug Saf. 2020;43(5):479-487.
18. Montastruc JL, Sommet A, Bagheri H, et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905-8.
19. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109-17.
20. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Available at: https://www.fda.gov/drugs/fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard (Accessed on 27th October 2024).
21. Faillie JL. Case-non-case studies: Principle, methods, bias and interpretation. Therapie. 2019;74(2):225-232.
22. Evans SJ. Pharmacovigilance: a science or fielding emergencies? Stat Med. 2000;19(23):3199-209.
23. Ahmed I, Haramburu F, Fourrier-Réglat A, et al. Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting. Stat Med. 2009;28(13):1774-92.
24. Muñoz MA, Tonning JM, Brinker AD, et al. Data Mining of the US FDA’s Adverse Events Reporting System Database to Evaluate Drug–Drug Interactions Associated with Statin-Induced Rhabdomyolysis. Pharm Med. 2016;30:327–337.
25. Fusaroli M, Salvo F, Begaud B, et al. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration. Drug Saf. 2024;47(6):585-599.
26. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
27. Julkunen RJ. The absorption of warfarin from the rat stomach in situ. Med Biol. 1976;54(4):260-3.
28. Zhang X, Wen H, Fan J, et al. Integrating In Vitro, Modeling, and In Vivo Approaches to Investigate Warfarin Bioequivalence. CPT Pharmacometrics Syst Pharmacol. 2017;6(8):523-531.
29. Tamemoto Y, Shibata Y, Hashimoto N, et al. Involvement of multiple cytochrome P450 isoenzymes in drug interactions between ritonavir and direct oral anticoagulants. Drug Metab Pharmacokinet. 2023;53:100498.
30. Jaber A, Al-Ani I, Hailat M, et al. Esomeprazole and apixaban pharmacokinetic interactions in healthy rats. Heliyon. 2022;8(10):e11015.
31. Mar PL, Gopinathannair R, Gengler BE, et al. Drug Interactions Affecting Oral Anticoagulant Use. Circ Arrhythm Electrophysiol. 2022;15(6):e007956.
32. Pauli-Magnus C, Rekersbrink S, Klotz U, et al. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001;364(6):551-7.
33. Chan EW, Lau WC, Leung WK, et al. Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study. Gastroenterology. 2015;149(3):586-95.e3.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.